Ionian University

Altoida Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

Retrieved on: 
Thursday, December 9, 2021
Software, Research, General Health, Pharmaceutical, Data Management, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, FDA, Health, Twitter, SVP, Research, Population, Digital, Health, Growth, Gold, AR, DBm, CB Insights, CEO, Lists of diseases, Intelligence, Work, 150, Ageing, CB, FDA, LinkedIn, Artificial intelligence, Digital health, Ionian University, Medical device

an AI company pioneering next-generation neurological disease diagnostics, to its third annual Digital Health 150 , which showcases the 150 most promising private digital health companies in the world.

Key Points: 
  • an AI company pioneering next-generation neurological disease diagnostics, to its third annual Digital Health 150 , which showcases the 150 most promising private digital health companies in the world.
  • This years Digital Health 150 was unveiled live during CB Insights annual Future of Health event.
  • Companies this year include startups working on data integration & analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more.
  • We are honored to be named to the CB Insights Digital Health 150 ranking.

Altoida and Ionian University Investigate Breakthrough Software Device for Parkinson's Disease Diagnosis

Retrieved on: 
Monday, October 25, 2021
Data Management, Other Science, Seniors, Technology, Research, Managed Care, Other Health, Consumer, Pharmaceutical, Mental Health, Genetics, Fitness & Nutrition, Clinical Trials, Biotechnology, Other Education, University, Software, Health, Education, Science, DBm, Diagnosis, Technology, LinkedIn, Neurodegeneration, Neuron, AR, Twitter, Ionian University, Partnership, Patient, FDA, TUM Department of Informatics, Bioinformatics, Parkinson's disease, Risk, Intelligence, Life, Smartphone, Biomarker, Health, Artificial intelligence, Therapy, Department, Medical device, Medical imaging

Altoida, Inc. the worlds leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University.

Key Points: 
  • Altoida, Inc. the worlds leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University.
  • The collaboration will investigate Altoidas medical device, an FDA Breakthrough Device being developed for early diagnosis and monitoring of Alzheimers disease, for early diagnosis and prediction of Parkinsons disease onset.
  • In that time, Altoida and BiHELab will apply and Altoidas technology to analysis of Parkinsons disease progression and evaluate its efficacy in diagnosing Parkinsons in the preclinical phase.
  • For Parkinsons patients, accurate prediction and early diagnosis could enable intervention before the extensive damage of dopaminergic neurons occurs."

Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University

Retrieved on: 
Monday, October 18, 2021
Education, Health, Medical Devices, Surgery, General Health, Other Education, University, HIV disease progression rates, MRI, AR, DBm, Smartphone, LinkedIn, Ionian University, Neurodegeneration, Headquarters, Alzheimer's disease, Disease, Physician, Department, MCI, Cognition, AI, Bioinformatics, TUM Department of Informatics, Non-functional testing, Ageing, Meta-analysis, Intelligence, Lists of diseases, FDA, Artificial intelligence, Patient, Dementia, Â, Pathology, PET, CEO, Twitter, Software, CSF, Genomics, Pharmaceutical industry, Medical device, Medical imaging

This landmark research study will be launched in collaboration with Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai), and the Bioinformatics and Human Electrophysiology Laboratory (BiHeLab), Department of Informatics at Ionian University.

Key Points: 
  • This landmark research study will be launched in collaboration with Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai), and the Bioinformatics and Human Electrophysiology Laboratory (BiHeLab), Department of Informatics at Ionian University.
  • We are launching the worlds most comprehensive study ever conducted in Alzheimers, and related neurological diseases, said Travis Bond, CEO of Altoida.
  • "Through this collaborative study with Altoida and Ionian University, we look forward to gaining new insights into the Alzheimer's Disease continuum from various aspects of rich data sets, said Keisuke Naito, Chief Ecosystem Officer of Eisai.
  • Altoida, Inc. is funded by M-Ventures, Eisai Innovation, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners.